论文部分内容阅读
[目的]探讨肺癌并上腔静脉综合征(superior vena cava syndrome,SVCS)患者血浆D-二聚体、血清CEA、CYFRA21-1水平变化及意义。[方法 ]60例肺癌合并SVCS的Ⅲ、Ⅳ期患者为实验组,60例未合并SVCS的Ⅲ、Ⅳ期患者作为对照组。给予两组患者三维适形放疗联合化疗治疗,检测血D-二聚体水平、血清CEA及CYFRA21-1水平。[结果]实验组患者治疗后的血D-二聚体、CEA、CYFRA21-1水平均显著低于治疗前(P<0.05),差异有统计学意义,与对照组比较无显著差异;治疗前实验组患者的D-二聚体、CEA、CYFRA21-1水平均显著高于对照组(P<0.05)。实验组缓解患者的D-二聚体、CEA、CYFRA21-1水平均显著低于未缓解患者(P<0.05)。[结论]肺癌并SVCS患者血液中具有较高的D-二聚体、CEA、CYFRA21-1水平,三维适形放疗联合化疗治疗能够有效降低其水平,改善患者预后。
[Objective] To investigate the changes and clinical significance of plasma D-dimer, serum CEA and CYFRA21-1 levels in patients with lung cancer and superior vena cava syndrome (SVCS). [Method] The 60 patients with stage Ⅲ and Ⅳ lung cancer complicated with SVCS were the experimental group and 60 patients with stage Ⅲ and Ⅳ without SVCS as the control group. Three-dimensional conformal radiotherapy combined with chemotherapy was given to the two groups of patients, and blood D-dimer levels, serum CEA and CYFRA21-1 levels were measured. [Results] The levels of D-dimer, CEA and CYFRA21-1 in the experimental group were significantly lower than those before treatment (P <0.05), and there was no significant difference between the two groups The levels of D-dimer, CEA and CYFRA21-1 in the experimental group were significantly higher than those in the control group (P <0.05). The levels of D-dimer, CEA and CYFRA21-1 in the remission patients in the experimental group were significantly lower than those in the non-remission patients (P <0.05). [Conclusion] The blood levels of D-dimer, CEA and CYFRA21-1 in patients with lung cancer and SVCS are high, and the three-dimensional conformal radiotherapy combined with chemotherapy can effectively reduce the level and improve the prognosis of patients.